Why the study?
Does continuous interscalene brachial plexus block with bupivacaine provide effective analgesia and safe plasma concentrations in patients undergoing shoulder surgery?
Does continuous interscalene brachial plexus block with bupivacaine provide effective analgesia and safe plasma concentrations in patients undergoing shoulder surgery?
Continuous interscalene brachial plexus block with bupivacaine provides effective postoperative analgesia for shoulder surgery with safe plasma concentrations, likely due to increased alpha 1-acid glycoprotein binding.
Answers are grounded in this paper and cite their sources.
May support continuous interscalene blocks for shoulder analgesia; hypothesis-generating and requires RCTs before practice change.
Continuous interscalene brachial plexus block with a single dose of 0.5% bupivacaine 1.25 mg/kg, continued with an infusion of 0.25% bupivacaine 0.25 mg/kg/h, was performed on 24 patients to provide analgesia during shoulder surgery and in the postoperative period. The drugs for general anaesthesia included glycopyrrolate, thiopentone, vecuronium, enflurane and N2O/O2. All patients had signs of regional analgesia 30 min after the block without haemodynamic problems. The infusion of local anaesthetic was interrupted in six patients because of a failure in catheter function. Of the remaining 18 patients, nine needed no complementary analgesics and nine patients received, on average, 1.6 doses of oxycodone (0.15 mg/kg/dose) during a 24-h period. Displacement of the interscalene catheters could be prevented by a fixation suture to the skin. Two patients noted a metallic taste during the bupivacaine infusion. The most common complaints were numbness of the hand (n = 15) and hoarseness (n = 5). The mean (+/- s.e.mean) plasma concentrations of bupivacaine at 30, 60, 180 min and 24 h were 0.68 +/- 0.06, 0.62 +/- 0.05, 0.52 +/- 0.04 and 0.76 +/- 0.01 micrograms/ml, respectively. During the 24-h period, the alpha 1-acid glycoprotein (AAG) concentration (mean +/- s.e.mean) in plasma rose from 0.41 +/- 0.04 g/l to 0.54 +/- 0.04 g/l (P less than 0.001). The concentration of free bupivacaine was below detectable levels (less than 0.01 micrograms/ml) after the 24-h infusion. The rise in AAG probably increases binding of bupivacaine to plasma proteins, diminishing the risk of systemic toxicity.
No takes yet. Share an insight, caveat, or question.
Tuominen et al. (1989) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: